Artificial intelligence was predictive of care strategies for patients with diabetic kidney disease, a new study found.
Test results from the KidneyIntelX diagnostic tool were significantly tied to how a primary care physician tailored a patient s treatment strategy, reported Manasi Datar, PhD, of Boston Healthcare Associates in Massachusetts, and colleagues.
Specifically, having a patient with a high-risk KidneyIntelX result was associated with a 64% (OR 1.64, 95% CI 1.29-2.08) higher odds of a primary care physician prescribing an SGLT-2 inhibitor with a diabetic kidney disease indication, such as canagliflozin (Invokana) which gained this expanded indication in September 2019.
The prognostic test identifying a patient as high risk was also tied to a 49% higher odds of the primary care physician increasing the patient s angiotensin II receptor blocker (ARB) dose (OR 1.49, 95% CI1.17-1.89) compared with patients who did not undergo this test.
Share this article
Share this article
NEW YORK, April 7, 2021 /PRNewswire/ Today, before the National Kidney Foundation s 2021 Spring Clinicals Meetings of thousands of kidney health professionals, hundreds of studies from the last year were presented including three studies considered late-breaking research papers.
The presentations were made at the virtual presentation at the annual Spring Clinical Meetings, which was held virtually for the second year due to COVID-19 restriction. The event is a chance for investigators to share their findings with professionals who attend the conference, which is one of the most respected gatherings of kidney professionals in the United States.
Cutting-edge Research Unveiled at National Kidney Foundation s Annual Professional Meeting prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.